Featured Research

from universities, journals, and other organizations

First the hype, now the science: Evidence-based recommendations for PRP

Date:
December 10, 2013
Source:
Northwestern Memorial Hospital
Summary:
A paper offers the first evidence-based recommendations for use of PRP in orthopaedic care. The authors determined which musculoskeletal conditions PRP is successful in treating and where more research is needed.

Platelet-rich plasma (PRP) has grabbed headlines in recent years for its role in helping some of sports' biggest stars return to play following injury -- including golfer Tiger Woods, Super Bowl winner Hines Ward and NBA legend Kobe Bryant.

Professional and amateur athletes alike seek PRP to address a wide-range of orthopaedic conditions, including injuries to the joints, ligaments, tendons and muscles. PRP is made by placing a sample of a patient's own blood in a centrifuge to concentrate the platelets, which are cells rich in growth factors. The PRP is then injected back into the injury to stimulate tissue growth and healing.

Use of PRP has proliferated in recent years especially in sports medicine where injured athletes are eager to recover faster and return to their sport. Despite its rising popularity, PRP remains a costly treatment rarely covered by insurance because little scientific evidence has supported its use -- until now.

A paper in the December issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) offers the first evidence-based recommendations for use of PRP in orthopaedic care. The authors, including two Northwestern Medicineฎ orthopaedic surgeons, determined which musculoskeletal conditions PRP is successful in treating and where more research is needed.

"The hype around PRP definitely came before the science," said Wellington Hsu, MD, the lead author on the paper, spine surgeon at Northwestern Memorial Hospital and assistant professor in orthopaedic surgery and neurological surgery at Northwestern University Feinberg School of Medicine. "In medicine, we rely on scientific evidence to support best use of treatments, but with PRP that hasn't been the case. Interest in PRP jumped way ahead of the research."

PRP does not involve any drugs or chemicals. "PRP is completely natural and uses the patient's own blood platelets to enhance the body's biological healing process," said Michael Terry, MD, co-author on the paper and an orthopaedic surgeon at Northwestern Memorial and associate professor of orthopaedic surgery at the Feinberg School. "There are very few documented complications associated with PRP; it's safe and has shown good results for many conditions."

The authors completed a comprehensive evaluation of published PRP research from around the world to develop their recommendations.

"While evidence suggests that PRP improves tissue healing, we also found that success varies depending on the preparation method and composition of the PRP, medical condition, location on the body and tissue type," Hsu said.

The authors concluded that current evidence supports PRP as a treatment for conditions including arthritis in the ankle and tennis elbow (lateral epicondylitis) and that injecting PRP during ACL reconstruction contributes to healing. When it comes to using PRP for osteoarthritis of the knee, the authors were encouraged by early research, but recommended further study.

They also suggested further study was needed in regards to Achilles tendon repair, rotator cuff injuries and other chronic tendinopathies aside from the elbow. PRP is not beneficial in bone healing applications and should not be used in spinal fusion or other bone grafting procedures, the authors concluded.

"We're hopeful that our findings can serve as a roadmap on how and when PRP is appropriate in orthopaedic care," said Terry. "Now that we have a better understanding of when this therapy is effective, we can tailor it to other applications. For example, if we know evidence supports PRP use for arthritic ankles and knees, it makes sense to start looking at it for osteoarthritis of the hip."

With scientific support now available, the costly treatment could eventually become more attainable for patients in the future.

"Insurers have not covered PRP because of the lack of science," said Hsu. "Patients currently pay out of pocket, sometimes thousands of dollars, to get PRP. With evidence-based recommendations, insurance companies hopefully will consider coverage for this therapy."


Story Source:

The above story is based on materials provided by Northwestern Memorial Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. W. K. Hsu, A. Mishra, S. R. Rodeo, F. Fu, M. A. Terry, P. Randelli, S. T. Canale, F. B. Kelly. Platelet-rich Plasma in Orthopaedic Applications: Evidence-based Recommendations for Treatment. Journal of the American Academy of Orthopaedic Surgeons, 2013; 21 (12): 739 DOI: 10.5435/JAAOS-21-12-739

Cite This Page:

Northwestern Memorial Hospital. "First the hype, now the science: Evidence-based recommendations for PRP." ScienceDaily. ScienceDaily, 10 December 2013. <www.sciencedaily.com/releases/2013/12/131210072127.htm>.
Northwestern Memorial Hospital. (2013, December 10). First the hype, now the science: Evidence-based recommendations for PRP. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/12/131210072127.htm
Northwestern Memorial Hospital. "First the hype, now the science: Evidence-based recommendations for PRP." ScienceDaily. www.sciencedaily.com/releases/2013/12/131210072127.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins